Шляхи оптимізації заходів стоматологічної реабілітації пацієнтів з метаболічним синдромом перед протезуванням на імплантатах

R. Symonenko; S. Vefelev

doi:10.33295/1992-576X-2025-3-90

Authors

R. Symonenko Bogomolets National Medical University, Kyiv, Ukraine https://orcid.org/0000-0003-4618-6229
S. Vefelev Bogomolets National Medical University, Kyiv, Ukraine https://orcid.org/0009-0002-3400-2285

DOI:

https://doi.org/10.33295/1992-576X-2025-3-90

Keywords:

metabolic syndrome, chronic periodontitis, diagnostics, dental implants, dental prosthetics

Abstract

Summary. Metabolic syndrome (MS) is a condition that combines several risk factors united by a common pathogenetic basis. It is a complex of metabolic disorders, which includes various combinations of abdominal obesity (AO), hyperglycemia, arterial hypertension (AH), and atherogenic dyslipidemia. Metabolic syndrome belongs to the group of modifiable risk factors that increase the likelihood of developing cardiovascular diseases (CVD), type 2 diabetes mellitus, and cognitive impairment, pronounced changes in the oral cavity organs through metabolic disorders, and low-intensity chronic inflammation. Among the dental changes in patients with metabolic syndrome, periodontal pathology takes a leading role, causing disorders of the dento-maxillary system, tooth loss, and, consequently, profound morphofunctional changes in the craniomandibular region. The severity of these changes depends on the degree of microcirculation disorders, the condition of the vascular walls, the level of mineral metabolism, and the general hygienic status of the oral cavity. The duration and severity of metabolic syndrome are closely related to systemic disorders in the body and oral tissues, increasing the risk of complications during the integration of dental implants and the subsequent functioning of orthopedic structures. Therefore, the search for effective therapeutic strategies for the correction of MS, especially in patients who require dental orthopedic rehabilitation with dental implants, is particularly relevant. This is crucial for improving prognosis and treatment outcomes, especially in cases of reconstructive surgery.

Downloads

Download data is not yet available.

Author Biographies

R. Symonenko, Bogomolets National Medical University, Kyiv, Ukraine

Candidate of Medical Sciences, Associate Professor of the Department of Orthopedic Dentistry

S. Vefelev, Bogomolets National Medical University, Kyiv, Ukraine

Postgraduate student of the Department of Dentistry, Institute of Postgraduate Education

References

Lam D.W., LeRoith D. Feingold K.R., Anawalt B., Blackman M.R. et al. (2019). Metabolic Syndrome. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. PMID: 25905173. (Electronic resource.) URL: https://pubmed.ncbi.nlm.nih.gov/25905173/. Bookshelf ID: NBK278936

Riahi S.M., Moamer S., Namdari M. et al.(2018). Patterns of clustering of the metabolic syndrome components and its association with coronary heart disease in the Multi Ethnic Study of Atherosclerosis (MESA): A latent class analysis. Int J Cardiol, 15, 271:13–18. DOI: https://doi.org/10.1016/j.ijcard.2018.05.080.

Salehinia F., Abdi H., Hadaegh F. et al. (2018). Abdominal obesity phenotypes and incident diabetes over 12 years of follow-up: The Tehran Lipid and glucose study. Diabetes Res Clin Pract, 144: 17–24. DOI: https://doi.org/10.1016/j.diabres.2018.07.021.

Ng T.P., Feng L., Nyunt M.S. et al. (2016). Metabolic Syndrome and the Risk of Mild Cognitive Impairment and Progression to Dementia: Follow-up of the Singapore Longitudinal Ageing Study Cohort. JAMA Neurol, 73(4): 456–463. DOI: https://doi.org/10.1001/jamaneurol.2015.4899.

Camus J.P. (1966). Goutte, diabète, hyperlipémie: un trisyndrome métabolique [Gout, diabetes, hyperlipemia: a metabolic trisyndrome]. Rev Rhum Mal Osteoartic, 33(1):10-4 (in French). PMID: 5910828.

Symonenko R. V., Etnis L. O. (2024). Modern methods of diagnosing periodontal tissue diseases in the concept of a systemic approach to treatment. (Literature review. Part 2). Actual Dentistry, 3: 24–30. DOI: https://doi.org/10.33295/1992-576X-2024-3-24.

Mehnert H., Kuhlmann H. (1968). Hypertonie und Diabetes mellitus [Hypertension and diabetes mellitus]. Dtsch Med J, 19(16): 567–71. (in German). PMID: 5702732.

Christlieb A.R., Krolewski A.S., Warram J.H., Soeldner J.S.( 1985). Is insulin the link between hypertension and obesity? Hypertension,7(6Pt2), II54–57. DOI: https://doi.org/10.1161/01.HYP.7.6_Pt_2.II54.

Modan M., Halkin H., Almog S. et al. (1985). Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest, 75(3): 809–817. DOI: https://doi.org/10.1172/JCI111776.

Ferrannini E., Buzzigoli G., Bonadonna R. et al. (1987). Insulin resistance in essential hypertension. N Engl J Med, 317(6): 350–357. DOI: https://doi.org/10.1056/NEJM198708063170605.

Lithell H., Haglund K., Granath F., Ostman J. (1988). Are effects of antihypertensive treatment on lipoproteins merely “side-effects”? A comparison of prazosin and metoprolol. Acta Med Scand, 223(6): 531–536. PMID: 3291559.

Kaplan N.M. (1989). The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med, 149(7): 1514–1520. DOI: https://doi.org/10.1001/archinte.149.7.1514.

Zimmet P.Z. (1992). Kelly West Lecture 1991. Challenges in diabetes epidemiology—from West to the rest. Diabetes Care, 15(2): 232–252. DOI: https://doi.org/10.2337/diacare.15.2.232.

Tonetti MS, Van Dyke TE. (2013). Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol, 84, 4S, S24-S29. DOI: https://doi.org/10.1902/jop.2013.1340019.

Ussar S., Fujisaka S., Kahn R. (2016). Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome. Mol Metab, 5(9): 795–803. DOI: https://doi.org/10.1016/j.molmet.2016.07.004.

Symonenko R. V. (2023). Modern methods of diagnosing periodontal tissue diseases in the concept of a systemic approach to treatment. (Literature review. Part 1). Actual Dentistry, 6: 14. DOI: https://doi.org/10.33295/1992-576X-2023-6-14.

Gurav AN. (2014). The association of periodontitis and metabolic syndrome. Dent Res J (Isfahan), 11(1): 1–10. PMID: 24688553. PMCID: PMC3955301

Papapanou PN, Sanz M, Buduneli N, et al (2018). Periodontitis: consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol, 89 Suppl 1, S173-S182. DOI: https://doi.org/10.1002/JPER.17-0721.

Blüher M. (2016). Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance? Clin Sci (Lond). 130(18): 1603–14. DOI: https://doi.org/10.1042/CS20160005.

Schulze M.B. (2019). Metabolic health in normal-weight and obese individuals. Diabetologia, 62(4), 558–566. DOI: https://doi.org/10.1007/s00125-018-4787-8.

Nielsen J. (2017). Systems Biology of Metabolism: A Driver for Developing Personalized and Precision Medicine. Cell Metab, 25(3): 572–579. DOI: https://doi.org/10.1016/j.cmet.2017.02.002.

Lovric A., Granér M., Bjornson E. et al. (2018). Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. Sci Rep, 8(1): 14200. DOI: https://doi.org/10.1038/s41598-018-31865-w.

Liu Z., Zhang C., Lee S. et al. (2019). Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function. Metab Eng, 52: 263–272. DOI: https://doi.org/10.1016/j.ymben.2019.01.001.